Related Experiment Video

Updated: Jan 6, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Mapping the evolution of immune checkpoint inhibitor research in small cell lung cancer: A bibliometric analysis

Ye Chen¹, Jing Zhu¹, Jie Wu¹

¹The Clinical Laboratory Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.

Human Vaccines & Immunotherapeutics

|October 30, 2025

Abstract:

Immune checkpoint inhibitors (ICIs) have revolutionized small cell lung cancer (SCLC) treatment, yet a comprehensive bibliometric analysis of global research trends is lacking. This study examines publication patterns, key contributors, and emerging research focuses on ICIs in SCLC using bibliometric tools. We analyzed 809 articles from the Web of Science Core Collection (1997-2025) with VOSviewer, CiteSpace, and Bibliometrix. Publications grew at 9.11% annually, with China (304 articles), the USA (201), and Japan (101) as top contributors. Leading institutions included the University of Texas System (105 articles) and UTMD Anderson Cancer Center (84). Frontiers in Oncology (38 articles) and Thoracic Cancer (32) were prominent journals. Key researchers were Wang J (21 articles, 1,706 citations) and Reck M (15 articles, 4,341 citations). Keyword analysis identified four clusters: (1) ICI mechanisms and immune-related molecules, (2) chemotherapy combinations, (3) clinical trial designs, and (4) ICI efficacy/safety. Burst terms included overall survival, radiation therapy, and placebo. Emerging trends highlight multimodal strategies, ICI-radiation synergy, and open-label trials. Research hotspots focus on ICI mechanisms, combination therapies, trial optimization, and safety. Future directions should explore predictive biomarkers, novel combinations, and tailored protocols to improve SCLC outcomes. This study provides a roadmap for advancing ICI research in SCLC, emphasizing global collaboration and translational innovation.

Keywords:

Small cell lung cancer bibliometric analysis immune checkpoint inhibitors immunotherapy

More Related Videos

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Articles linked to this work by shared authors, journal, and citation graph.

[Karyomorphology research in seven kinds of dandelion in Northeast].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·2012

A silver(I)-catalyzed tandem reaction of 2-alkynylbenzaldoxime with alkylidenecyclopropane.

Organic letters·2012

An unexpected silver triflate-catalyzed tandem reaction of N'-(2-alkynylbenzylidene)hydrazide with ketene.

Chemical communications (Cambridge, England)·2012

Generation of polyfluoroaryl-fused H-pyrazolo[5,1-a]isoquinolines through a reaction of N'-(2-alkynylbenzylidene)hydrazide with polyfluoroarene.

Chemistry, an Asian journal·2012

Cooperation of protease-activated receptor 1 and integrin ανβ5 in thrombin-mediated lung cancer cell invasion.

Oncology reports·2012

α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation.

Journal of neuroinflammation·2012

See all related articles